Treatment of Induced Mesenchymal Stem Cells in Ischemic Heart Diseases: Hypoxia

When traditional methods fall short in treating ischemic heart diseases caused by reduced blood flow to the heart due to narrowed coronary arteries, alternative solutions such as cellular therapies are thought. Mesenchymal stem cells (MSCs) are advantageous due to their ease of isolation, migration, and immunomodulatory properties. Preconditioning, which involves regulating cell functions through external stimuli, enhances the effectiveness of cellular therapy. Hypoxia, known as oxygen deprivation, is known to regulate cell survival, migration, and differentiation capabilities. This review explores the current state and future of hypoxia preconditioning in enhancing the therapeutic effects of stem cells.